Core Viewpoint - DBV Technologies has successfully raised €166.7 million through the full exercise of ABSA and BS Warrants, which will support the launch of the VIASKIN® Peanut patch for children aged 4 to 7 years in the U.S., pending approval [1][11]. Financing Details - The financing involved the issuance of 34,090,004 ABSA Warrants and 71,005,656 BS Warrants, leading to the issuance of 59,657,507 new ordinary shares and up to 124,259,898 pre-funded warrants [1][5]. - The exercise price for the ABSA Warrants was €1.5939, while the BS Warrants had an exercise price of €1.5764 [1][6]. Use of Proceeds - The gross proceeds from the exercise will be utilized for working capital, general corporate purposes, and to finance the preparation and submission of a potential Biologics License Application (BLA) for the VIASKIN® Peanut patch [10][11]. - The total financing, including potential exercises of outstanding warrants, is estimated to reach approximately €284.5 million [10]. Shareholder Impact - The issuance of new shares will dilute existing shareholders' equity, with ownership interest for a shareholder holding 1.00% of the Company's share capital decreasing to 0.78% on a non-diluted basis after the issuance [15]. - The shareholding structure will change post-issuance, with Baker Brothers Investments retaining 8.64% and Janus Henderson acquiring 7.54% of the diluted share capital [17]. Company Overview - DBV Technologies is a late-stage biopharmaceutical company focused on developing treatments for food allergies using its proprietary VIASKIN® patch technology [19]. - The company is headquartered in Châtillon, France, with operations in North America [20].

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period†). Vistagen is a clinical-stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegati. ...

As filed with the U.S. Securities and Exchange Commission on January 16, 2026 Registration No. 333-292331 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ ESTRELLA IMMUNOPHARMA, INC. (Exact Name of Registrants as Specified in its Charter) ____________________________ | Delaware | 6770 | 86-1314502 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard I ...

Biopharmaceutical company Agomab Therapeutics filed for an initial public offering in the United States on Friday. ...

Designation further supports (Z)-Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pediatric Disease Designation SEATTLE, Jan. 16, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced that the U.S. Food and Drug Administration ("FDA") Office of Orphan Products Development ("OOPD") ha ...

Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PTSOUTH SAN FRANCISCO, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced that it will host a conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET (5:00 am PT) to report the results from cohort 4 of the randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with ...

As filed with the Securities and Exchange Commission on January 16, 2026 Registration No. 333-291852 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Edison Oncology Holding Corp. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Nevada 2836 83-1614120 (I.R.S. Employer Identification Number) 3475 Edison Way, S ...

On January 6, Dan Ives of Wedbush Securities joined ‘Closing Bell’ on CNBC to suggest that the tech bull market continues to play out. Ives referred to Nvidia’s Jensen Huang as the godfather of AI and predicted that Huang would plant the flag for the next chapter of the AI revolution. This phase transitions the narrative beyond just hardware and chips toward end-to-end involvement in robotics and autonomous tech. Ives argued that this shift toward robotics and autonomy is currently not factored into the sto ...

BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the closing of its previously announced Company best efforts registered direct offering ("Offering") of 7,040,000 ordinary shares at an offering price of $1.25 per ordinary share conducted without an underwriter or placement agent to members of senior management and existing shareh ...

Group 1: Debt Financing Trends - The increasing reliance on debt for financing multi-billion-dollar artificial intelligence and AI-infrastructure investments has raised concerns, with Oracle being a notable example, potentially raising $20-$30 billion in debt annually over the next three years for its AI initiatives [1][2] - Many large companies are accumulating debt to enhance their AI capabilities, with $37 billion in U.S. investment-grade bonds issued on the first Monday of 2026, and an estimated $215 billion of high-grade debt expected to be sold in January alone [3] Group 2: Corporate Debt Risks - Rising leverage poses risks, as increased debt levels may lead to higher corporate defaults, while companies with minimal or no debt generally have better financial flexibility and less operational volatility during downturns [4] - An optimal balance between leveraging debt for growth and maintaining financial stability is essential for companies to capitalize on investment opportunities [4] Group 3: Debt-Free Stock Selection - The article defines "debt-free" as companies with net cash positions where enterprise value is lower than market capitalization, indicating that cash and liquid investments exceed total debt [5] - A methodology was established to identify the best debt-free stocks, focusing on U.S. stocks with a market capitalization of at least $2 billion and an enterprise value-to-market cap ratio below 1.0, leading to a shortlist of stocks with a potential upside of at least 15% and high hedge fund ownership [7][8] Group 4: Company-Specific Insights - Coinbase Global Inc. (NASDAQ:COIN) is highlighted as a top debt-free stock with a potential upside of 48.4%, receiving an upgrade from BofA, which noted that the recent stock decline was unrelated to fundamentals [10][11] - Insmed Inc. (NASDAQ:INSM) reported strong preliminary 2025 results with total revenue of approximately $606 million, a 67% year-over-year increase, driven by its leading therapies [15][16] - Palo Alto Networks Inc. (NASDAQ:PANW) is recognized as a debt-free stock with a potential upside of 22.5%, although UBS has maintained a cautious stance due to softness in platformization deals and potential deceleration in service revenue growth [20][22]